It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Lithuania: Refusal of a patent application and its consequences, Court of Appeal of Lithuania, 2A-162-798/2016, 4 March 2016
-
Res iudicata in a divisional application/CANON, European Patent Office (EPO Board of Appeal), 07 May 2009
-
Patent case: Raytheon Company, EPO
-
Almirall v. Mylan, Court of Appeal Brussels (Hof van Beroep te Brussel), 23 June 2009
-
Specification may not normally be used to restrict the scope of protection of claims
-
Allocation of Access Rights (UMTS), Court of Appeal Karlsruhe (Oberlandesgericht Karlsruhe), 11 May 2009
-
The Role of Scientific Advisers in the English Patents Court
-
Unified Patent Courts will hardly bifurcate proceedings
-
Inventive step, Priority right, Second Medical Use, Sufficiency of disclosure, United Kingdom, Validity
Hospira clears the way for generic Herceptin
-
USA: Tile Tech, Inc. v. United Construction Products, Inc, United States Court of Appeals, Federal Circuit, No. 2016-1392, 15 December 2016